Hao Yin



        Hao Yin


        Medical Research Institute

        Frontier Science Center for Immunology and Metabolism

        Wuhan University, Wuhan, China

                                       Email: haoyin@whu.edu.cn


2003    B.S.  Biotechnology    Nanjing University

2010    Ph.D Toxicology University of Colorado Anshutz Medical Campus

Professional Experience and Academic Appointments

2010-2016 Postdoctoral Associate Massachusetts Institute of Technology

Mentor: Robert Langer and Daniel Anderson

2016-2018 Research Scientist Vertex Pharmaceuticals

2018-present Professor Medical Research Institute, Wuhan University

Professional Activities

• Journal Referee (ad hoc)

Journal of the American Chemical Society (JACS); Nature Communications; Chemical Reviews;Chemical Science;Molecular Therapy;Nucleic Acids Research, and many others.

• Editorial Board Member

Toxicology Letters


Research Areas:

New genome editing tools

Next generation delivery systems for therapeutic genome editing


Research Areas:

• New approaches to manipulating the genome, epigenome and transcriptome

• Next generation delivery systems for therapeutic genome editing

Selected Publications

1. Wang L….. Yang B*, Yin H*, Yang L*, Chen J*, Nature Cell Biology, In press  

2. Song CQ, Jiang T, Richter M, Rhym LH, Koblan LW, Zafra MP, Schatoff EM, Doman JL, Cao Y, Dow LE, Zhu LJ, Anderson DG, Liu DR*, Yin H*, Xue W*, Adenine base editing in an adult mouse model of tyrosinaemia. Nature Biomedical Engineering. 2020 Jan;4(1):125-130.

Journal highlight: “Correcting tyrosinaemia via a point mutation” and “Towards better base editing” Nature Biomedical Engineering (2020)

3. Lu S, Li F, Chen Q, Wu J, Duan J, Lei X, Zhang Y, Zhao D, Bu Z*, Yin H* Rapid detection of African swine fever virus using Cas12a-based portable paper diagnostics Cell Discovery 2020 volume 6:18 

4. Yin H*, Xue W*, Anderson DG*. CRISPR-Cas: a tool for cancer research and therapeutics. Nature Reviews Clinical Oncology. 2019 May;16(5):281-295.

Selected in “100 papers collection” by Nature to celebrate 2020 Nobel Prize in Chemistry


5. Chen Q, Zhang Y*, Yin H*, Recent advances in chemical modifications of guide RNA, mRNA and donor template for CRISPR-mediated genome editing. Advanced Drug Delivery Reviews 2021 Jan;168:246-258 

6. Wu J, Yin H*. Engineering guide RNA to reduce the off-target effects of CRISPR. Journal of Genetics and Genomics. 2019 Nov 20;46(11):523-529.

7. Zhang HX, Zhang Y*, Yin H*. Genome Editing with mRNA Encoding ZFN, TALEN, and Cas9. Molecular Therapy. 2019 Apr 10;27(4):735-746

8. Yin H#, Song CQ#, Suresh S, Kwan SY, Wu Q, Walsh S, Ding J, Bogorad RL, Zhu LJ, Wolfe SA, Koteliansky V, Xue W, Langer R, Anderson DGPartial DNA-guided Cas9 enables genome editing with reduced off-target activity. Nature Chemical Biology 2018, 14(3):311-316.

*Journal highlight: Nature Catalysis “Better guidance is cheaper”Featured by BioCentury | Altering Cas9 and its guide for fewer off-target edits.

Selected in “100 papers collection” by Nature to celebrate 2020 Nobel Prize in Chemistry

9. Yin H, Song CQ, Suresh S, Wu Q, Walsh S, Rhym LH, Mintzer E, Bolukbasi MF, Zhu LJ, Kauffman K, Mou H, Oberholzer A, Ding J, Kwan SY, Bogorad RL, Zatsepin T, Koteliansky V, Wolfe SA, Xue W, Langer R, Anderson DG. Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing. Nature Biotechnology 2017, 35(12):1179-1187.

*Featured by VOICE of America / US Researchers Use Nanotech, Gene Editing to Edit Cholesterol Gene VICE / CRISPR Can Now Edit Genes Using Nanoparticles Instead of Viruses

Yahoo News / CNBC / Nanotech, gene editing used to edit cholesterol gene-US study

Genetic Engineering & Biotechnology News / CRISPR/Cas9 Delivery Goes Nano with Enhanced Guide RNA Fiercebiotech / MIT scientists propose a safer way to edit genes with CRISPR / MIT News / Science Daily / Bioscience Technology / Medical News Today/Business Insider UK / The Medical News / Phys.org.

10. Yin H, Kauffman KJ and Anderson DG. Delivery technologies for genome editing. Nature Reviews Drug Discovery 2017, 16(6): 387-399.

11. Yin H, Song CQ, Dorkin JR, Zhu L, Li Y, Wu Q, Park A, Yang J, Suresh S, Bizhanova A, Gupta A, Bolukbasi M, Walsh S, Bogorad R, Gao G, Weng Z, Dong Y, Koteliansky V, Wolfe S, Langer R, Xue W and Anderson DG. Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo. Nature Biotechnology 2016,34(3):328-33.

*Featured by MIT News / Science Daily / Bioscience Technology / Medical News Today / Deutsches Ärzteblatt / Nanowerk / Nanotechnology Now /The Medical News / Phys.org

12. Yin H#, Bogorad RL#, Barnes C, Walsh S, Zhuang I, Nonaka H, Ruda V, Kuchimanchi S, Nechev L, Akinc A, Xue W, Zerial M, Langer R, Anderson DG, Koteliansky V. RNAi-nanoparticulate manipulation of gene expression as a new functional genomics tool in the liver. Journal of Hepatology 2016, 64(4):899-907.

13. Mou H, Kennedy Z, Anderson DG, Yin H*, and Xue W*, Precision cancer mouse models through genome editing with CRISPR-Cas9. Genome Medicine 2015, 7(1):53.

14. Yin H#, Xue W#, Chen S, Bogorad RL, Benedetti E, Grompe M, Koteliansky V, Sharp PA, Jacks T, Anderson DG (2014) Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nature Biotechnology 2014, 32(6):551-3.

*100 top stories of 2014 by Discover Magazine as “A Giant Step for Gene Surgery”

*Top Ten Genetics Stories for 2014: Incredible Achievements, by the DNA Exchange

*Journal highlight: Nature Medicine (CRISPR technology for gene therapy) | A cover story in Science–Business eXchange of Nature Publishing Group | BioTechniques

*Featured by MIT News / The Independent: Front Page Headlines / Fox News / The Times of India / Science Daily / Medical daily / The Voice of Russia / Phys.org / F1000Prime Recommendation.

Selected in “100 papers collection” by Nature to celebrate 2020 Nobel Prize in Chemistry

15. Xue W#, Chen S#, Yin H#, Tammela T, Joshi N, Papagiannakopoulos T, Cai W, Yang G, Bronson R, Crowley D, Zhang F, Anderson DG, Sharp PA, Jacks T. CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature 2014, 514(7522):380-4.

*Journal highlight: Hepatology (Cutting short the path to murine liver cancer models)

*Featured by MIT News / Science Daily / Medical Press / Newswise / F1000Prime Recommendation.

16. Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, Anderson DG. Non-viral vectors for gene-based therapy. Nature Reviews Genetics 2014, 15(8):541-55.

17. Bogorad RL#, Yin H#, Zeigerer A, Nonaka H, Ruda VM, Zerial M, Anderson DG, Koteliansky V Nanoparticle-formulated siRNA targeting integrins inhibits hepatocellular carcinoma progression in mice. Nature Communications 2014, 5:3869.

*Journal highlight: Nature Reviews Gastroenterology & Hepatology (Loss of integrin β1 impairs liver regeneration and HCC progression)

18. Yin H, Cheng L, Holt M, Hail N, Jr., Maclaren R, Ju C, “Lactoferrin protects against acetaminophen-induced liver injury in mice”, Hepatology 2010, doi: 10.1002/hep.23476.

19. Yin H, Cheng L, Langenbach R, Ju C, “Prostaglandin I(2) and E(2) mediate the protective effects of cyclooxygenase-2 in a mouse model of immune-mediated liver injury”, Hepatology 2007, doi: 10.1002/hep.21493.

Book Chapter

"Genome Editing for Genetic Lung Diseases" Pharmaceutical Inhalation Aerosol Technology, Third Edition

Chimeric DNA-RNA Guide RNA Designs. Methods Mol Biol. 2021;2162:79-85



Tel: 0086-27-68750205 Fax: 0086-27-68759675  Email: mri@whu.edu.cn

Contact address: Donghu Road, No. 115, Wuchang District, Wuhan, Hubei Province, P.R. China. 430071

Copyright @ 2016 Medical Research Institute